| Literature DB >> 28620373 |
Ralf J Ludwig1, Karen Vanhoorelbeke2, Frank Leypoldt3,4,5, Ziya Kaya6, Katja Bieber1, Sandra M McLachlan7, Lars Komorowski8, Jie Luo9, Otavio Cabral-Marques10, Christoph M Hammers11, Jon M Lindstrom9, Peter Lamprecht10, Andrea Fischer6, Gabriela Riemekasten10, Claudia Tersteeg2, Peter Sondermann12, Basil Rapoport7, Klaus-Peter Wandinger13, Christian Probst8, Asmaa El Beidaq14, Enno Schmidt1, Alan Verkman15,16, Rudolf A Manz14, Falk Nimmerjahn17.
Abstract
Autoantibodies are frequently observed in healthy individuals. In a minority of these individuals, they lead to manifestation of autoimmune diseases, such as rheumatoid arthritis or Graves' disease. Overall, more than 2.5% of the population is affected by autoantibody-driven autoimmune disease. Pathways leading to autoantibody-induced pathology greatly differ among different diseases, and autoantibodies directed against the same antigen, depending on the targeted epitope, can have diverse effects. To foster knowledge in autoantibody-induced pathology and to encourage development of urgently needed novel therapeutic strategies, we here categorized autoantibodies according to their effects. According to our algorithm, autoantibodies can be classified into the following categories: (1) mimic receptor stimulation, (2) blocking of neural transmission, (3) induction of altered signaling, triggering uncontrolled (4) microthrombosis, (5) cell lysis, (6) neutrophil activation, and (7) induction of inflammation. These mechanisms in relation to disease, as well as principles of autoantibody generation and detection, are reviewed herein.Entities:
Keywords: B cells; autoantibodies; autoimmunity; diagnosis; mouse models; pathogenesis; treatment
Year: 2017 PMID: 28620373 PMCID: PMC5449453 DOI: 10.3389/fimmu.2017.00603
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561